Your browser doesn't support javascript.
loading
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
Sun, Chong; Wang, Liqin; Huang, Sidong; Heynen, Guus J J E; Prahallad, Anirudh; Robert, Caroline; Haanen, John; Blank, Christian; Wesseling, Jelle; Willems, Stefan M; Zecchin, Davide; Hobor, Sebastijan; Bajpe, Prashanth K; Lieftink, Cor; Mateus, Christina; Vagner, Stephan; Grernrum, Wipawadee; Hofland, Ingrid; Schlicker, Andreas; Wessels, Lodewyk F A; Beijersbergen, Roderick L; Bardelli, Alberto; Di Nicolantonio, Federica; Eggermont, Alexander M M; Bernards, Rene.
Afiliação
  • Sun C; 1] Division of Molecular Carcinogenesis, Cancer Systems Biology Centre and Cancer Genomics Centre Netherlands, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands [2].
  • Wang L; 1] Division of Molecular Carcinogenesis, Cancer Systems Biology Centre and Cancer Genomics Centre Netherlands, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands [2].
  • Huang S; 1] Division of Molecular Carcinogenesis, Cancer Systems Biology Centre and Cancer Genomics Centre Netherlands, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands [2] Department of Biochemistry, The Rosalind and Morris Goodman Cancer Centre, McGill University, Montr
  • Heynen GJ; Division of Molecular Carcinogenesis, Cancer Systems Biology Centre and Cancer Genomics Centre Netherlands, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
  • Prahallad A; Division of Molecular Carcinogenesis, Cancer Systems Biology Centre and Cancer Genomics Centre Netherlands, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
  • Robert C; Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France.
  • Haanen J; Division of Medical Oncology, Cancer Systems Biology Centre and Cancer Genomics Centre Netherlands, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
  • Blank C; Division of Medical Oncology, Cancer Systems Biology Centre and Cancer Genomics Centre Netherlands, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
  • Wesseling J; Division of Pathology, Cancer Systems Biology Centre and Cancer Genomics Centre Netherlands, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
  • Willems SM; 1] Division of Molecular Carcinogenesis, Cancer Systems Biology Centre and Cancer Genomics Centre Netherlands, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands [2] Department of Pathology, University Medical Centre Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, T
  • Zecchin D; 1] University of Torino, Department of Oncology, Str prov 142 Km 3.95, 10060 Candiolo, Torino, Italy [2] Candiolo Cancer Institute - FPO, IRCCS, Str prov 142 Km 3.95, 10060 Candiolo, Torino, Italy.
  • Hobor S; Candiolo Cancer Institute - FPO, IRCCS, Str prov 142 Km 3.95, 10060 Candiolo, Torino, Italy.
  • Bajpe PK; Division of Molecular Carcinogenesis, Cancer Systems Biology Centre and Cancer Genomics Centre Netherlands, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
  • Lieftink C; Division of Molecular Carcinogenesis, Cancer Systems Biology Centre and Cancer Genomics Centre Netherlands, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
  • Mateus C; Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France.
  • Vagner S; Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France.
  • Grernrum W; Division of Molecular Carcinogenesis, Cancer Systems Biology Centre and Cancer Genomics Centre Netherlands, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
  • Hofland I; Division of Pathology, Cancer Systems Biology Centre and Cancer Genomics Centre Netherlands, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
  • Schlicker A; Division of Molecular Carcinogenesis, Cancer Systems Biology Centre and Cancer Genomics Centre Netherlands, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
  • Wessels LF; Division of Molecular Carcinogenesis, Cancer Systems Biology Centre and Cancer Genomics Centre Netherlands, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
  • Beijersbergen RL; Division of Molecular Carcinogenesis, Cancer Systems Biology Centre and Cancer Genomics Centre Netherlands, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
  • Bardelli A; 1] University of Torino, Department of Oncology, Str prov 142 Km 3.95, 10060 Candiolo, Torino, Italy [2] Candiolo Cancer Institute - FPO, IRCCS, Str prov 142 Km 3.95, 10060 Candiolo, Torino, Italy [3] FIRC Institute of Molecular Oncology (IFOM), 20139 Milano, Italy.
  • Di Nicolantonio F; 1] University of Torino, Department of Oncology, Str prov 142 Km 3.95, 10060 Candiolo, Torino, Italy [2] Candiolo Cancer Institute - FPO, IRCCS, Str prov 142 Km 3.95, 10060 Candiolo, Torino, Italy.
  • Eggermont AM; Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France.
  • Bernards R; Division of Molecular Carcinogenesis, Cancer Systems Biology Centre and Cancer Genomics Centre Netherlands, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Nature ; 508(7494): 118-22, 2014 Apr 03.
Article em En | MEDLINE | ID: mdl-24670642
Assuntos
Antineoplásicos/administração & dosagem; Antineoplásicos/farmacologia; Melanoma/tratamento farmacológico; Inibidores de Proteínas Quinases/administração & dosagem; Inibidores de Proteínas Quinases/farmacologia; Proteínas Proto-Oncogênicas B-raf/genética; Animais; Proliferação de Células/efeitos dos fármacos; Senescência Celular/efeitos dos fármacos; Resistencia a Medicamentos Antineoplásicos/efeitos dos fármacos; Resistencia a Medicamentos Antineoplásicos/genética; Receptores ErbB/biossíntese; Receptores ErbB/genética; Receptores ErbB/metabolismo; Feminino; Citometria de Fluxo; Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos; Biblioteca Gênica; Humanos; Indóis/administração & dosagem; Indóis/farmacologia; Melanoma/enzimologia; Melanoma/genética; Melanoma/patologia; Camundongos; Quinases de Proteína Quinase Ativadas por Mitógeno/antagonistas & inibidores; Quinases de Proteína Quinase Ativadas por Mitógeno/metabolismo; Proteínas Proto-Oncogênicas B-raf/antagonistas & inibidores; Proteínas Proto-Oncogênicas B-raf/metabolismo; RNA Interferente Pequeno; Receptores Proteína Tirosina Quinases/biossíntese; Receptores Proteína Tirosina Quinases/genética; Receptores Proteína Tirosina Quinases/metabolismo; Receptor beta de Fator de Crescimento Derivado de Plaquetas/biossíntese; Receptor beta de Fator de Crescimento Derivado de Plaquetas/genética; Receptor beta de Fator de Crescimento Derivado de Plaquetas/metabolismo; Fatores de Transcrição SOXE/deficiência; Fatores de Transcrição SOXE/genética; Transdução de Sinais/efeitos dos fármacos; Sulfonamidas/administração & dosagem; Sulfonamidas/farmacologia; Fator de Crescimento Transformador beta/metabolismo; Fator de Crescimento Transformador beta/farmacologia; Vemurafenib
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Proto-Oncogênicas B-raf / Inibidores de Proteínas Quinases / Melanoma / Antineoplásicos Idioma: En Ano de publicação: 2014 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Proto-Oncogênicas B-raf / Inibidores de Proteínas Quinases / Melanoma / Antineoplásicos Idioma: En Ano de publicação: 2014 Tipo de documento: Article